Navigation Links
Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875

OSAKA, Japan, Oct. 18, 2011 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiaries, Takeda Global Research & Development Center, Inc. ("TGRD U.S."), and Takeda Global Research & Development Centre (Europe), Ltd. ("TGRD Europe"), announced today the initiation of the Company's Phase 3 clinical trial program for TAK-875, an investigational therapy for type 2 diabetes. The program will be conducted across the United States (U.S.), Latin America, and Europe. TAK-875 is the first GPR40 agonist to reach late stage (Phase 3) clinical development.

Completed studies of TAK-875, discovered by Takeda, have suggested glucose-lowering effects in patients with type 2 diabetes by enhancing glucose-dependent insulin secretion.

"Takeda is committed to enhancing the clinical investigation of TAK-875 in order to accelerate the development of a potential new type 2 diabetes treatment option for patients and healthcare professionals," said Thomas Strack, M.D., vice president, clinical science, Takeda Global Research & Development Center, Inc., U.S. "An outcome of our robust focus on diabetes over many years, TAK-875 was discovered by Takeda based on our GPCR research and is the first GPR40 agonist to reach late stage (Phase 3) clinical development. TAK-875 is being developed globally, with Phase 3 trials already underway in Japan."

The first Phase 3 trial in the U.S./Europe program, a double-blind, randomized, 24-week safety and efficacy study, will enroll approximately 450 patients with type 2 diabetes who are not adequately controlled on diet and exercise, at approximately 140 sites in the U.S., Latin America, and Europe. The study's primary endpoint will be the change in HbA1c at week 24 while other endpoints will include the assessment of a clinically meaningful response based on reaching HbA1c targets, changes in fasting plasma glucose (FPG) and two-hour postprandial plasma glucose (PPG). Results are expected by 2014.

About Type 2 Diabetes

Type 2 diabetes is the most common form of diabetes and has reached epidemic proportions globally. The number of people worldwide living with diabetes (both type 1 and type 2) has reached 366 million, and the disease is responsible for 4.6 million deaths each year. Type 2 diabetes is a progressive and chronic condition and patients should work with a health care professional to manage and monitor their disease. In addition to diet and exercise, patients often need to take medications in order to help manage glucose control. The global health care expenditures to treat and prevent diabetes and its complications have reached $465 billion.

About TAK-875

TAK-875 is one of Takeda's investigational therapies for type 2 diabetes. TAK-875 is a selective agonist of GPR40, one of the G-protein-coupled receptors that are expressed in pancreatic islet cells. GPR40 agonists have a mechanism of action for type 2 diabetes different from that of sulfonylureas (such as glimepiride). They work by selectively improving glucose-dependent insulin secretion with a potential for reduced risk of hypoglycemia. Additional Phase 3 clinical trials for TAK-875 were initiated in Japan in September 2011.

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website,

About Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc.

Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc. are subsidiaries of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. The respective companies currently market oral diabetes, insomnia, rheumatology, gastroenterology, and cardiovascular treatments and seek to bring innovative products to patients through a pipeline that includes compounds in development for metabolic and cardiovascular disease, gastroenterology, neurology and other conditions. To learn more about these Takeda companies, visit

About Takeda Global Research & Development Centre (Europe) Ltd.

Based in London, England, Takeda Global Research & Development Centre (Europe) Ltd. (TGRD Europe) is a subsidiary of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. TGRD Europe seeks to bring innovative products to patients through a pipeline that includes compounds in development for diabetes, cardiovascular disease, neurology, oncology and other conditions.

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Takeda Completes Acquisition and Names New CEO of Nycomed
2. Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program
3. Takeda Resubmits New Drug Applications in the U.S. for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
4. Takeda Responds to U.S. Food and Drug Administration Update to Safety Review of ACTOS (pioglitazone HCl)
5. Takeda to Acquire Nycomed
6. Amylin and Takeda Voluntarily Suspend Clinical Activities in Obesity Trial
7. Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia
8. Handa Pharmaceuticals Announces Submission of Its First-to-File ANDA for Takedas DEXILANT®
9. Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension
10. Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles
11. Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride)
Post Your Comments:
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Cell Surface Testing Market: Supplier Shares, ... their offering.  --> ... the  "2016 Future Horizons and Growth ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... --> adds "Global ... and "Investigation Report on China Repaglinide ... 2021 forecasts data and information to ... . --> ...
(Date:11/25/2015)... 2015 ... "Global Brain Monitoring Devices Market 2015-2019" ... ) has announced the addition ... Market 2015-2019" report to their offering. ... ) has announced the addition of ...
Breaking Medicine Technology:
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly styled ... These classically-influenced trailer titles work with any font, giving users limitless opportunities to ...
(Date:11/26/2015)... ... ... Inc., developer and distributor of the world-class Asterisk based contact center software Q-Suite, announces ... new Q-Suite 6 platform is based on the latest Java Enterprise standards. By conforming ... of software for many key components of the suite. Much of the suite runs ...
(Date:11/25/2015)... ... November 25, 2015 , ... As part of a global ... attracts volunteers together who want to combine talents and resources to help create ... the process. The non-profit launched its first major fundraiser on November 6, 2015 ...
(Date:11/25/2015)... , ... November 25, 2015 , ... Finnleo, a leader ... Eve on several models of traditional and far-infrared saunas. , For traditional ... is the most traditional Finnish sauna wood, and Finnleo uses only European Grade A ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... offering factory direct sauna parts and accessories. , Sauna accessories help improve the ... bather’s style and personality. From basic styles for the purist looking for simplicity ...
Breaking Medicine News(10 mins):